ImmunoCellular Therapeutics to Report Third Quarter 2017 Financial Results on November 21, 2017
Download PDF Version
Los Angeles, CA (PRNewswire) November 17, 2017
-- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to report third quarter 2017 financial results on Tuesday, November 21, 2017. The Company also plans to hold a conference call and webcast on that day at 5:00 pm ET to discuss the third quarter 2017 financial results and provide a business update. The call will be hosted by Anthony Gringeri, PhD, President and CEO.
(877) 853-5636 (toll-free); international dial-in: (631) 291-4544; conference code 3689426.
Interested parties who wish to listen to the webcast should visit the Investor Relations section of ImmunoCellular's website at www.imuc.com, under the Events and Presentations tab. A replay of the webcast will be available one hour after the conclusion of the event.
The conference call will contain forward-looking statements. The information provided on the teleconference is accurate only at the time of the conference call, and ImmunoCellular will take no responsibility for providing updated information except as required by law.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd., based in Los Angeles, is developing immune-based therapies for the treatment of cancer. ImmunoCellular is focused on advancing its Stem-to-T-Cell research program, which engineers hematopoietic stem cells to generate cytotoxic T cells. Additional assets, for which the Company is seeking partners, include clinical-stage programs - ICT-107, ICT-121 and ICT-140 - which are patient-specific, dendritic cell-based immunotherapies targeting solid tumors. To learn more about ImmunoCellular, please visit www.imuc.com.
ImmunoCellular Therapeutics, Ltd.
View original content with multimedia:http://www.prnewswire.com/news-releases/immunocellular-therapeutics-to-report-third-quarter-2017-financial-results-on-november-21-2017-300558273.html
SOURCE ImmunoCellular Therapeutics, Ltd.